167 related articles for article (PubMed ID: 28146138)
21. Selected pro-inflammatory cytokines, bone metabolism, osteoprotegerin, and receptor activator of nuclear factor-kB ligand in girls with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Marek B; Świętochowska E; Kajdaniuk D; Strzelczyk J; Cieślicka A; Wołkowska-Pokrywa K; Kos-Kudła B
Endokrynol Pol; 2015; 66(4):313-21. PubMed ID: 26323468
[TBL] [Abstract][Full Text] [Related]
22. Soluble receptor activator of nuclear factor- kappaB Ligand (sRANKL)/osteoprotegerin balance in ageing and age-associated diseases.
Pulsatelli L; Dolzani P; Silvestri T; Caraceni P; Facchini A; Ravaglia G; Salvarani C; Melicòni R; Mariani E
Biogerontology; 2004; 5(2):119-27. PubMed ID: 15105586
[TBL] [Abstract][Full Text] [Related]
23. Bone metabolism, osteoprotegerin, receptor activator of nuclear factor-κB ligand and selected adipose tissue hormones in girls with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Świętochowska E; Marek B; Kajdaniuk D; Wołkowska-Pokrywa K; Kos-Kudła B
Endokrynol Pol; 2014; 65(1):33-9. PubMed ID: 24549600
[TBL] [Abstract][Full Text] [Related]
24. Dehydroepiandrosterone sulfate, osteoprotegerin and its soluble ligand sRANKL and bone metabolism in girls with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Swiętochowska E; Wołkowska-Pokrywa K
Postepy Hig Med Dosw (Online); 2012 Sep; 66():655-62. PubMed ID: 23001207
[TBL] [Abstract][Full Text] [Related]
25. Serum osteoprotegrin (OPG) and receptor activator of nuclear factor kappaB (RANKL) in healthy children and adolescents.
Wasilewska A; Rybi-Szuminska AA; Zoch-Zwierz W
J Pediatr Endocrinol Metab; 2009 Dec; 22(12):1099-104. PubMed ID: 20333868
[TBL] [Abstract][Full Text] [Related]
26. Similar to adiponectin, serum levels of osteoprotegerin are associated with obesity in healthy subjects.
Ashley DT; O'Sullivan EP; Davenport C; Devlin N; Crowley RK; McCaffrey N; Moyna NM; Smith D; O'Gorman DJ
Metabolism; 2011 Jul; 60(7):994-1000. PubMed ID: 21087777
[TBL] [Abstract][Full Text] [Related]
27. Elevated serum levels of soluble receptor activator of nuclear factors-kappaB ligand (sRANKL) and reduced bone mineral density in patients with ankylosing spondylitis (AS).
Kim HR; Lee SH; Kim HY
Rheumatology (Oxford); 2006 Oct; 45(10):1197-200. PubMed ID: 16567356
[TBL] [Abstract][Full Text] [Related]
28. Circulating RANKL and RANKL/OPG and Breast Cancer Risk by ER and PR Subtype: Results from the EPIC Cohort.
Sarink D; Schock H; Johnson T; Overvad K; Holm M; Tjønneland A; Boutron-Ruault MC; His M; Kvaskoff M; Boeing H; Lagiou P; Papatesta EM; Trichopoulou A; Palli D; Pala V; Mattiello A; Tumino R; Sacerdote C; Bueno-de-Mesquita HBA; van Gils CH; Peeters PH; Weiderpass E; Agudo A; Sánchez MJ; Chirlaque MD; Ardanaz E; Amiano P; Khaw KT; Travis R; Dossus L; Gunter M; Rinaldi S; Merritt M; Riboli E; Kaaks R; Fortner RT
Cancer Prev Res (Phila); 2017 Sep; 10(9):525-534. PubMed ID: 28701332
[TBL] [Abstract][Full Text] [Related]
29. Decreased level of soluble receptor activator of nuclear factor-κβ ligand (sRANKL) in overweight and obese children.
Erazmus M; Rumińska M; Witkowska-Sędek E; Kucharska AM; Stelmaszczyk-Emmel A; Majcher A; Pyrżak B
Front Endocrinol (Lausanne); 2022; 13():963467. PubMed ID: 36060948
[TBL] [Abstract][Full Text] [Related]
30. Age and gender predict OPG level and OPG/sRANKL ratio in maintenance hemodialysis patients.
Naumnik B; Klejna K; Koc-Żórawska E; Myśliwiec M
Adv Med Sci; 2013; 58(2):382-7. PubMed ID: 23959668
[TBL] [Abstract][Full Text] [Related]
31. Variations along the 24-hour cycle of circulating osteoprotegerin and soluble RANKL: a rhythmometric analysis.
Dovio A; Generali D; Tampellini M; Berruti A; Tedoldi S; Torta M; Bonardi S; Tucci M; Allevi G; Aguggini S; Bottini A; Dogliotti L; Angeli A
Osteoporos Int; 2008 Jan; 19(1):113-7. PubMed ID: 17703272
[TBL] [Abstract][Full Text] [Related]
32. Osteoprotegerin and RANKL serum levels and their relationship with serum ghrelin in children with chronic renal failure and on dialysis.
Ozkaya O; Buyan N; Bideci A; Gonen S; Ortac E; Fidan K; Cinaz P; Söylemezoğlu O
Nephron Clin Pract; 2007; 105(4):c153-8. PubMed ID: 17259742
[TBL] [Abstract][Full Text] [Related]
33. Assessment of the relationship between melatonin, hormones of the pituitary-ovarian, -thyroid and -adrenocortical axes, and osteoprotegerin and its ligand sRANKL in girls with anorexia nervosa.
Ostrowska Z; Ziora K; Oświęcimska J; Wołkowska-Pokrywa K; Szapska B
Postepy Hig Med Dosw (Online); 2013 May; 67():433-41. PubMed ID: 23752595
[TBL] [Abstract][Full Text] [Related]
34. RANKL and OPG gene polymorphisms: associations with vertebral fractures and bone mineral density in premenopausal systemic lupus erythematosus.
Bonfá AC; Seguro LP; Caparbo V; Bonfá E; Pereira RM
Osteoporos Int; 2015 May; 26(5):1563-71. PubMed ID: 25609157
[TBL] [Abstract][Full Text] [Related]
35. Soluble receptor activator of nuclear factor-kappaB ligand (RANKL) and osteoprotegerin in ankylosing spondylitis: OPG is associated with poor physical mobility and reflects systemic inflammation.
Chen CH; Chen HA; Liao HT; Liu CH; Tsai CY; Chou CT
Clin Rheumatol; 2010 Oct; 29(10):1155-61. PubMed ID: 20690034
[TBL] [Abstract][Full Text] [Related]
36. Increased expression of receptor activator of NF-kappaB ligand (RANKL), its receptor RANK and its decoy receptor osteoprotegerin in the colon of Crohn's disease patients.
Franchimont N; Reenaers C; Lambert C; Belaiche J; Bours V; Malaise M; Delvenne P; Louis E
Clin Exp Immunol; 2004 Dec; 138(3):491-8. PubMed ID: 15544627
[TBL] [Abstract][Full Text] [Related]
37. Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1.
Neirich L; Yahiaoui-Doktor M; Lammert J; Basrai M; Seethaler B; Berling-Ernst A; Ramser J; Quante AS; Schmidt T; Niederberger U; Rhiem K; Schmutzler R; Engel C; Bischoff SC; Halle M; Kiechle M; Grill S
Breast Cancer Res Treat; 2021 Dec; 190(3):463-475. PubMed ID: 34570303
[TBL] [Abstract][Full Text] [Related]
38. Changes in the serum levels of osteoprotegerin and soluble receptor activator for nuclear factor kappaB ligand after estrogen-progestogen therapy and their relationships with changes in bone mass in postmenopausal women.
Kim JG; Kim JH; Lee DO; Kim H; Kim JY; Suh CS; Kim SH; Choi YM
Menopause; 2008; 15(2):357-62. PubMed ID: 17925661
[TBL] [Abstract][Full Text] [Related]
39. Association between osteoprotegerin (OPG), receptor activator of nuclear factor-kappaB (RANK), and RANK ligand (RANKL) gene polymorphisms and circulating OPG, soluble RANKL levels, and bone mineral density in Korean postmenopausal women.
Kim JG; Kim JH; Kim JY; Ku SY; Jee BC; Suh CS; Kim SH; Choi YM
Menopause; 2007; 14(5):913-8. PubMed ID: 17667143
[TBL] [Abstract][Full Text] [Related]
40. Potential role of the OPG/RANK/RANKL axis in prostate cancer invasion and bone metastasis.
Li X; Liu Y; Wu B; Dong Z; Wang Y; Lu J; Shi P; Bai W; Wang Z
Oncol Rep; 2014 Dec; 32(6):2605-11. PubMed ID: 25333856
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
